Warning: Undefined array key "ref" in /home/elite/public_html/chat/key/bit.php on line 24

Warning: Undefined array key "ref" in /home/elite/public_html/chat/key/bit.php on line 24

Warning: Undefined array key "ref" in /home/elite/public_html/chat/key/bit.php on line 24
Zacks Equity Research, Author at Elite Stock Chat - Page 234 of 401

Author: Zacks Equity Research

HOG – Key Predictions for Harley-Davidson's (HOG) Q2 Earnings

Harley-Davidson Inc. (HOG Free Report) is slated to release second-quarter 2021 results on Jul 21, before the opening bell. The Zacks Consensus Estimate for the quarter’s earnings and revenues is pegged at $1.15 a share and $1.37 billion, respectively.

In the last reported quarter, the U.S. motorcycle giant reported adjusted earnings of $1.68 per share, handily beating the Zacks Consensus Estimate of 79 cents on the back of higher-than-anticipated income from both Motorcycles & Related Products as well as Financial Services segments.

Over the trailing four quarters, the company beat earnings estimates on two occasions for as many misses, with the average negative surprise being 365.7%. This is depicted in the graph below:

Trend in Estimate Revisions

The Zacks Consensus Estimate for Harley-Davidson’s second-quarter earnings per share has remained unrevised in the past 30 days. The bottom-line projection indicates a massive turnaround from the year-ago period’s loss of 60 cents a share. The Zacks Consensus Estimate for quarterly revenues also suggests a year-over-year surge of 104.3%.

Earnings Whispers

Our proven model does not conclusively predict an earnings beat for Harley-Davidson this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. However, that is not the case here as elaborated below.

Earnings ESP: It has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Zacks Rank: Harley-Davidson currently flaunts a Zacks Rank of 1. You can see the complete list of today’s Zacks #1 Rank stocks here.

Factors at Play

Efforts to rebrand itself, improve product mix and cater better to younger generations are likely to have benefited Harley-Davidson’s sales in the quarter to be reported. Also, with the economy on the recovery track, thanks to massive fiscal stimulus and widespread inoculation drive, motorcycle sales of the firm are expected to have soared from the year-ago quarter, which was badly hit by the pandemic-led sluggish demand.

Evidently, the Zacks Consensus Estimate for motorcycle units retailed in the United States for second-quarter 2021 is pegged at 42,309, suggesting an uptick from 31,340. The consensus mark for retail sales in the Asia Pacific and EMEA regions also point to year-over-year growth of around 15% each. The consensus estimate for total worldwide retail sales is 66,887 units, indicating an increase from 52,712 units sold in second-quarter 2020. As such, the consensus mark for revenues from the Motorcycle & Related Products unit is pegged at $1,381 million, signaling whopping growth of 106.4% year over year.

The firm’s Rewire turnaround plan led to efficiency and effectiveness across all functions. This is likely to get reflected in its operating profit. The Zacks Consensus Estimate for operating profit from the Motorcycle & Related Products segment stands at $177 million, suggesting a turnaround from a loss of $121 million incurred in the comparable quarter of 2020.

On the flip side, Harley-Davidson’s high capex requirements associated with product innovation and digital advancement are likely to have strained its already weak financials and limited cash flows. High commodity costs are also anticipated to have weighed on the company’s gross profit in second-quarter 2021.

Stocks With Favorable Combinations

Here are a few auto stocks worth considering, as these have the right combination of elements to come up with an earnings beat this time around:

Tesla (TSLA Free Report) has an Earnings ESP of +5.85% and carries a Zacks Rank #2 at present. The company is set to announce second-quarter 2021 results on Jul 26.

PACCAR (PCAR Free Report) has an Earnings ESP of +1.81% and holds a Zacks Rank #3 at present. The company is scheduled to announce fourth-quarter 2020 results on Jul 27.

Cummins (CMI Free Report) has an Earnings ESP of +2.51% and carries a Zacks Rank #3 at present. The company is slated to announce second-quarter 2021 results on Aug 3.

BMRN – BioMarin (BMRN) Gets EMA Validation for Hemophilia Gene Therapy

BioMarin Pharmaceutical Inc. (BMRN Free Report) announced that the European Medicines Agency (“EMA”) has validated its marketing authorization application (“MAA”) seeking approval for its investigational gene therapy, valoctocogene roxaparvovec, for treating adult patients with severe hemophilia A.

Following this validation, the review of the MAA for valoctocogene roxaparvovec can finally begin. An opinion from the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) is expected in the first half of 2022.

The MAA filing includes safety and efficacy data from the phase III GENEr8-1 study which evaluated valoctocogene roxaparvovec in 134 subjects, along with four- and three-year follow-up data from the 6e13 vg/kg and 4e13 vg/kg dose cohorts, respectively, of the ongoing phase I/II dose escalation study.

Last month, BioMarin re-submitted the MAA for valoctocogene roxaparvovec to the European Commission. The company had withdrawn the MAA for valoctocogene roxaparvovec in the EU last year.

In May 2021, the EMA granted accelerated assessment for the review of valoctocogene roxaparvovec. The accelerated assessment is likely to reduce the time period for the EMA’s CHMP and Committee for Advanced Therapies to review the MAA for valoctocogene roxaparvovec from 210 days to 150 days.

Share of BioMarin have plunged 9.3% so far this year compared with the industry’s decrease of 4.1%.

Zacks Investment Research
Image Source: Zacks Investment Research

We remind investors that in August last year, the FDA issued a complete response letter (“CRL”) to valoctocogene roxaparvovec’s biologics license application (“BLA”) ahead of the Aug 21 PDUFA date as it was not satisfied with the available data. The FDA asked for two-year follow-up data on annualized bleed rates from the ongoing phase III GENEr8-1 study in order to have additional evidence of a durable effect. The data is not expected to be available before November 2021. Back then, BioMarin also withdrew its marketing application in the EU.

Investors were expecting the FDA to grant accelerated approval to the drug on the PDUFA date. It was expected that valoctocogene roxaparvovec, if approved, would be a transformational product as it has the potential to dramatically change the treatment paradigm. However, the CRL and the delayed BLA filing have now pushed potential approval of valoctocogene roxaparvovec to 2023, which is a major blow to BioMarin’s prospects. A BLA on the same is expected to be re-filed to the FDA in the second quarter of 2022.

Hemophilia A is a genetic disorder caused by missing or defective factor VIII. Despite being prescribed the current standard-of-care medicines, severe hemophilia A patients persistently experience painful bleeds, thereby creating significant need for medicines that can improve patients’ quality of life. Several companies are developing gene therapy products to treat severe hemophilia A.

Sangamo Therapeutics (SGMO Free Report) , along with partner Pfizer (PFE Free Report) , is evaluating their gene therapy candidate, giroctocogene fitelparvovec (SB-525), in a phase III study for hemophilia A. Swiss pharma giant Roche (RHHBY Free Report) and Dutch biotech, uniQure, are also developing gene therapy candidates to treat hemophilia A.

Zacks Rank

BioMarin currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

AMZN – Amazon (AMZN) HealthLake Boosts AWS for Health Offerings

Amazon’s (AMZN Free Report) cloud computing platform, Amazon Web Services (AWS) recently made Amazon HealthLake — a service eligible under the Health Insurance Portability and Accountability Act of 1996 — generally available for healthcare and life sciences organizations.

This service uses analytics and machine learning to analyze and extract important health-related information, and securely store them in the cloud.

Amazon HealthLake uses the Fast Healthcare Interoperability Resources industry standard format for easier data exchange across healthcare systems, pharmaceutical companies, clinical research firms and others. This helps organizations to collaborate and bring new therapies, quickly deliver vaccines to the market as well as discover health trends in patient populations.

It also enables medical professionals to maintain a holistic profile of their patients and provide medication according to their needs.

AWS Portfolio Strength: Key Catalyst

The latest move by Amazon has strengthened its AWS for Health offerings. AWS for Health offers a portfolio of solutions to healthcare, biopharma and genomics organizations to help them discover, assess as well as deploy cloud solutions for better business and patient outcomes.

Amazon is making strong efforts to expand the AWS portfolio of services in order to maintain its dominance in the cloud computing market.

Recently, Amazon announced the availability of an application delivery service called AWS Proton that the company announced in early June. AWS Proton helps developers to seamlessly provision, deploy and monitor applications.

The Amazon Location Service that helps customers securely add location functionality to their applications has also been launched.

In late May, AWS launched Amazon Elastic Container Service (ECS) Anywhere that offers consistent tooling and APIs for all container-based applications. This service enables customers to have the same Amazon ECS experience for cluster management, workload scheduling, and monitoring in cloud and data centers.

Additionally, it made available AWS APP Runner in mid-May. This service is a fully managed container application service that helps developers to seamlessly build, deploy, and run containerized web applications and APIs.

Amazon DevOps Guru and Amazon FinSpace were introduced in early May. While the former helps developers to improve applications, the latter helps Financial Services Industry Organizations to seamlessly search, prepare and analyze data.

Growing Customer Base to Aid Prospects

The Amazon HealthLake service launch is expected to help AWS gain strong traction among various customers. Customers and partners including Rush University Medical Center, Cortica, CureMatch, MEDHOST, InterSystems and Redox have already shown interest in Amazon HealthLake.

Further, AWS continues to witness growth in customer base due to its robust portfolio of services.

Last month, AWS was selected by Swisscom (SCMWY Free Report) as its cloud provider. Swisscom will leverage AWS’s analytics, machine learning, containers, database and storage services for its enterprise IT.

In the same month, Ferrari (RACE Free Report) selected AWS as its official cloud, machine learning and artificial intelligence provider to bring advancements across its road cars department, GT Competitions, the Ferrari Challenge and the Scuderia Ferrari FORMULA 1.

AWS was also selected by BMO Financial Group as its cloud provider. BMO will leverage AWS’ analytics, machine learning, serverless, compute, storage, and database for upgrading its banking platforms as well as developing digital financial services applications.

In late April, AWS was selected by The Walt Disney (DIS Free Report) for globally expanding its online streaming video service, Disney+.

This expanding customer base will continue to drive top-line growth of AWS, which generated $13.5 billion revenues in first-quarter 2021, up 32% year over year, accounting for 12% of revenues.

Currently, Amazon carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

AN – Can AutoNation (AN) Maintain Its Earnings Beat Streak in Q2?

AutoNation, Inc. (AN Free Report) is slated to release second-quarter 2021 results on Jul 19, before the opening bell. The Zacks Consensus Estimate for the quarter’s earnings and revenues is pegged at $2.65 per share and $5.94 billion, respectively.

AutoNation, the largest automotive retailer in the United States, delivered better-than-expected results in the last reported quarter on higher-than-anticipated revenues from new and used vehicles. Operational efficiency also aided the bottom line. 

In the preceding four quarters, the company surpassed the Zacks Consensus Estimate on all occasions, with the average being 103.6%. This is depicted in the graph below:

Trend in Estimate Revisions

The Zacks Consensus Estimate for AutoNation’s second-quarter earnings per share has been revised upward by 12 cents over the past seven days. The bottom-line projection indicates an improvement from the year-ago earnings of $1.41 per share. Moreover, the Zacks Consensus Estimate for quarterly revenues suggests a year-over-year rise of 31%.

Earnings Whispers

Our proven model predicts an earnings beat for AutoNation this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat.

Earnings ESP: The company has an Earnings ESP of 33.44%. This is because the Most Accurate Estimate is pegged 89 cents above than the Zacks Consensus Estimate. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Zacks Rank: AutoNation currently carries a Zacks Rank of 2. You can see the complete list of today’s Zacks #1 Rank stocks here.

Factors to Note

Demand for vehicles in second-quarter 2021 had been strong amid preference for personal mobility, widespread vaccination drive, unprecedented federal aid and the gradual reopening of activities. This is likely to have driven AutoNation’s sales in the quarter to be reported. AutoNation’s heightened focus on providing enhanced digital solutions is anticipated to have fueled sales during the quarter in discussion. Increasing prices of used vehicles are also expected to have driven revenues.

The consensus mark for revenues of new and used vehicles is pegged at $3,171 million and $1,723 million, indicating an increase from the year-ago level of $2,261 million and $1,325 million, respectively. Additionally, the consensus estimate for revenues from Finance & Insurance and Parts & Services segments is pegged at $309 million and $872 million, indicating 25.6% and 26.4% growth, respectively.

Sharpened focus on cost discipline is anticipated to have aided margins. All in all, robust sales across all segments and operational discipline are set to drive AutoNation’s second-quarter 2021 results.

Other Stocks With Favorable Combinations

Here are a few other auto stocks having the right combination of elements to come up with an earnings beat this time around:

Tesla (TSLA Free Report) has an Earnings ESP of +5.85% and flaunts a Zacks Rank #2 at present. The company is set to announce second-quarter 2021 results on Jul 26.

PACCAR (PCAR Free Report) has an Earnings ESP of +1.81% and holds a Zacks Rank #3 at present. The company is scheduled to announce fourth-quarter 2020 results on Jul 27.

Cummins (CMI Free Report) has an Earnings ESP of +2.51% and carries a Zacks Rank #3 at present. The company is slated to announce second-quarter 2021 results on Aug 3.

VIR – Vir Biotech (VIR) Begins Dosing in Phase II Hepatitis B Study

Vir Biotechnology, Inc. (VIR Free Report) announced that it has dosed the first patient in the phase II MARCH study which is evaluating VIR-2218 in combination with VIR-3434 for the treatment of patients with chronic hepatitis B virus (“HBV”) infection. The combination of VIR-2218 plus VIR-3434 is being developed to achieve a functional cure for the given indication.

The open-label, multi-center study will evaluate the safety, tolerability and efficacy of the combination of VIR-2218 + VIR-3434 in patients aged 18 to 65 years with chronic HBV infection, who are receiving nucleot(s)ide reverse transcriptase inhibitor therapy.

The primary endpoints of the study are to check the proportion of patients with treatment-emergent adverse/serious adverse events, grading of post-treatment clinical laboratory parameters and the proportion of patients achieving a functional cure.

Shares of Vir Biotechnology have rallied 35.5% so far this year against the industry’s decrease of 4%.

Zacks Investment Research
Image Source: Zacks Investment Research

Per the company, VIR-2218, an investigational siRNA, is designed to inhibit the production of all HBV proteins, while VIR-3434 is an investigational HBV-neutralizing monoclonal antibody designed to block the entry of all 10 genotypes of HBV into hepatocytes, as well as reduce the level of virions and subviral particles in blood.

Vir Biotechnology has been actively seeking partnerships to develop therapeutic antibody treatments for various respiratory viruses and other infections.

We remind investors that Vir Biotechnology has a partnership with GlaxoSmithKline (GSK Free Report) for developing therapeutic antibody treatments for COVID-19 infection. In May 2021, the FDA granted Emergency Use Authorization (“EUA”) to their dual-action monoclonal antibody sotrovimab (previously VIR-7831) for high-risk COVID-19.

The EUA is for treating mild-to-moderate COVID-19 in adult and pediatric patients (at least 12 years of age and weighing at least 40 kg) who are at risk of progression to severe COVID-19, including hospitalization or death. A formal biologics license application for sotrovimab to the FDA is expected to be filed in the second half of 2021.

Zacks Rank & Stocks to Consider

Vir Biotechnology currently carries a Zacks Rank #5 (Strong Sell).

Top-ranked stocks in the biotech sector include Repligen Corporation (RGEN Free Report) and Bio-Techne Corporation (TECH Free Report) , both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Repligen’s earnings estimates have been revised 2.2% and 1.2% upward for 2021 and 2022, respectively, over the past 60 days. The stock has rallied 2.9% year to date.

Bio-Techne’s earnings estimates have been revised 2.3% and 4% upward for 2021 and 2022, respectively, over the past 60 days. The stock has surged 41.6% year to date.

RHI – Robert Half (RHI) to Report Q2 Earnings: What's in the Cards?

Robert Half International Inc. (RHI Free Report) is scheduled to report second-quarter 2021 results on Jul 22, after the bell.

The company has an impressive earnings surprise history. It surpassed the Zacks Consensus Estimate in all of the trailing four quarters, delivering an earnings surprise of 18.7%, on average.

Expectations This Time Around

The Zacks Consensus Estimate for Robert Half’s revenues in the to-be-reported quarter is pegged at $1.48 billion, indicating 33.9% growth from the year-ago reported figure. With the staffing industry gradually reviving from the pandemic-induced blow, the company’s top line is expected to have benefited from increase in both Staffing and Protiviti revenues.

The bottom line is likely to have benefited from operating strength, the consensus mark for which is pegged at $1.05 per share, signaling more than 100% year-over-year growth.

What Our Model Says

Our proven model does not conclusively predict an earnings beat for Robert Half this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Robert Half has an Earnings ESP of 0.00% and a Zacks Rank #3.

You can see the complete list of today’s Zacks #1 Rank stocks here.

Stocks That Warrant a Look

Here are a few other stocks from the broader Zacks Business Services sector that investors may consider, as our model shows that these have the right combination of elements to beat on earnings this season.

Omnicom (OMC Free Report) , with an Earnings ESP of +10.19% and a Zacks Rank #3.

Aptiv (APTV Free Report) , with an Earnings ESP of +8.44% and currently carrying a Zacks Rank of 3.

(WEX Free Report) , with an Earnings ESP of +3.47% and carrying a Zacks Rank of 3.

KMX – Why CarMax (KMX) is a Top Momentum Stock for the Long-Term

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.

Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.

It also includes access to the Zacks Style Scores.

What are the Zacks Style Scores?

Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.

Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.

The Style Scores are broken down into four categories:

Value Score

Value investors love finding good stocks at good prices, especially before the broader market catches on to a stock’s true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.

Growth Score

While good value is important, growth investors are more focused on a company’s financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.

Momentum Score

Momentum investors, who live by the saying “the trend is your friend,” are most interested in taking advantage of upward or downward trends in a stock’s price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.

VGM Score

What if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank

A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company’s earnings outlook, to help investors create a successful portfolio.

#1 (Strong Buy) stocks have produced an unmatched +25.41% average annual return since 1988, which is more than double the S&P 500’s performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.

But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.

That’s where the Style Scores come in.

You want to make sure you’re buying stocks with the highest likelihood of success, and to do that, you’ll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only as a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.

Since the Scores were created to work together with the Zacks Rank, the direction of a stock’s earnings estimate revisions should be a key factor when choosing which stocks to buy.

A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: CarMax (KMX Free Report)

Headquartered in Richmond, VA, CarMax Inc. operates as a specialty retailer of used and new vehicles. The range of vehicles includes both cars and light trucks. It is one of the largest retailers of used vehicles in the United States. CarMax also provides customers with a full range of related services including financing of vehicle purchases and sale of extended warranties, accessories and vehicle repair services through CarMax Auto Finance (CAF).

KMX is a #1 (Strong Buy) on the Zacks Rank, with a VGM Score of B.

Momentum investors should take note of this Retail-Wholesale stock. KMX has a Momentum Style Score of B, and shares are up 13.2% over the past four weeks.

For fiscal 2022, five analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.64 to $6.43 per share. KMX boasts an average earnings surprise of 41.9%.

With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, KMX should be on investors’ short list.

CMG – Chipotle (CMG) to Report Q2 Earnings: What's in the Offing?

Chipotle Mexican Grill, Inc. (CMG Free Report) is scheduled to report second-quarter 2021 results on Jul 20. In the last reported quarter, the company delivered an earnings surprise of 8.9%.

How Are Estimates Placed?

The Zacks Consensus Estimate for second-quarter earnings is pegged at $6.46, indicating growth of 1,515% from 40 cents registered in the year-ago quarter.

For revenues, the consensus mark is pegged at nearly $1,875 million that suggests increase of 37.4% from the prior-year quarter’s figure.

Let’s discuss the factors that are likely to get reflected in the quarter to be reported.

 

Factors at Play

Chipotle’s second-quarter performance is likely to have benefitted from initiatives involving disciplined approach to creativity and innovation as well as leveraging digital capabilities to drive productivity and expand access, convenience and engagement. To this end, the transition of the company’s digital ecosystem from a commerce system to a platform of engagement through enhancements in app, website and group offerings are encouraging. Moreover, the idea of leveraging digital scale and removing operational friction with respect to its digital kitchen is likely to have driven second-quarter performance. Given the initiatives, the company expects its trailing 12-month average unit volumes to pass $2.4 million in the second quarter.

Meanwhile, Chipotle’s second-quarter top line is likely to reflect an improvement in comps on the back of healthy demand for Carne Asada, rise in delivery menu prices, normalizing quesadilla incidents and lower marketing investments. The company expects second-quarter comps in the range of high 20-30%.

This along with focus on Chipotlane add-ons, alternative store formats, digital-only menu offerings and Chipotle rewards is likely to have boosted the company’s performance in the to-be-reported quarter.

However, rise in menu items such as avocado along with a surge in delivery and service fees are likely to have hurt margins in the second quarter. Food costs for the quarter is expected to be in mid to high 30% range.

What Our Model Says

Our proven model predicts an earnings beat for Chipotle this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat.

Earnings ESP: Chipotle has an Earnings ESP of +5.53%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Zacks Rank: The company has a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.

Stocks Poised to Beat Earnings Estimates

Here are some other stocks from the Zacks Retail-Wholesale space that investors may consider as our model shows that these also have the right combination of elements to post an earnings beat this quarter:

Papa John’s International, Inc. (PZZA Free Report) currently carries a Zacks Rank #2 and has an Earnings ESP of +6.56%.

BJ’s Restaurants, Inc. (BJRI Free Report) carries a Zacks Rank #2 and has an Earnings ESP of +8.51%.

Chuy’s Holdings, Inc. (CHUY Free Report) carries a Zacks Rank #2 and has an Earnings ESP of +1.02%.

KMI – Is a Beat in Store for Kinder Morgan's (KMI) Q2 Earnings?

Kinder Morgan, Inc. (KMI Free Report) is set to beat earnings estimates when it reports second-quarter 2021 results on Jul 21.  

In the last reported quarter, the leading energy infrastructure company’s adjusted earnings per share of 60 cents beat the Zacks Consensus Estimate of 23 cents, thanks to higher contribution from Texas intrastate systems and the Tennessee Gas Pipeline during winter storm in February. Favorable conditions in the CO2 segment boosted the results. This was partially offset by lower demand for terminal assets and refined products.

Kinder Morgan’s earnings beat the Zacks Consensus Estimate twice, missed on another occasion and met the same once in the trailing four quarters, with the average surprise being 42%. This is depicted in the graph below:

Let’s see how things have shaped up prior to this announcement.

Trend in Estimate Revision

The Zacks Consensus Estimate for second-quarter earnings per share of 19 cents has witnessed no revision over the past seven days. The estimated figure suggests a rise of 11.8% from the prior-year reported number.

The consensus estimate for second-quarter revenues of $2.96 billion indicates a 15.6% increase from the year-ago reported figure.

What the Quantitative Model Suggests

Our proven model predicts an earnings beat for Kinder Morgan this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat.

Earnings ESP: Earnings ESP for the company is currently +14.07%. This is because the Most Accurate Estimate is pegged at 22 cents per share, higher than the Zacks Consensus Estimate of 19 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.  

Zacks Rank: Kinder Morgan currently carries a Zacks Rank #3.

Factors Driving the Better-Than-Expected Earnings

As the North American market witnessed a rapid recovery in energy demand from last year’s historic downturn, the company is expected to have seen higher utilization of midstream infrastructure assets in the second quarter. Being a leading midstream energy firm, Kinder Morgan is likely to have generated stable fee-based revenues in the quarter from the gigantic natural gas transportation network that spreads across roughly 70,000 miles.

Its $2.2-billion Permian Highway Pipeline project started full commercial operations in the beginning of 2021 and transports additional daily natural gas volumes of roughly 2.1 billion cubic feet. This is expected to have led to a year-over-year rise in natural gas transportation to the U.S. Gulf Coast, thereby resulting in higher profit levels.

The Elba Island Liquefaction facility, wherein Unit 7 came online in the second half of last year, is expected to have boosted the company’s liquefied natural gas (LNG) exports year over year. With rising LNG demand in Asian economies, Kinder Morgan is expected to have earned higher fees from LNG exporting assets in the June quarter.

Other Stocks to Consider

Here are some other companies from the Energy space that you may also want to consider, as our model shows that these too have the right combination of elements to post an earnings beat in the upcoming quarterly reports:

EOG Resources, Inc. (EOG Free Report) has an Earnings ESP of +5.31% and a Zacks Rank of 3. It is scheduled to report second-quarter results on Aug 4. You can see the complete list of today’s Zacks #1 Rank stocks here.

Hess Corporation (HES Free Report) has an Earnings ESP of +35.30% and is a Zacks #1 Ranked player. The company is scheduled to release second-quarter results on Jul 28.

Continental Resources, Inc. (CLR Free Report) has an Earnings ESP of +10.61% and a Zacks Rank #1. The firm is scheduled to release quarterly earnings on Aug 2.

NFLX – Netflix (NFLX) Set to Report Q2 Earnings: What to Expect?

Netflix (NFLX Free Report) is set to report second-quarter 2021 results on Jul 20.

The company forecasts first-quarter earnings to be $3.16 per share. The Zacks Consensus Estimate for earnings has remained stable at $3.16 per share in the past 30 days. The figure indicates 98.7% growth from the year-ago quarter’s reported figure.

Further, total revenues are anticipated to be $7.3 billion, up 18.8% year over year. The consensus mark for second-quarter revenues is currently pegged at $7.31 billion, suggesting 18.9% growth from the figure reported in the year-earlier quarter.

Notably, the company missed the Zacks Consensus Estimate in three of the trailing four quarters, while beating in one. It has a trailing four-quarter negative earnings surprise of 4.96%, on average.

Let’s see how things are shaping up for this announcement.

Factors to Consider

Netflix currently operates in a saturated streaming market in the United States. It is expected to have faced stiff competition from new streaming providers like Disney+ by Disney (DIS Free Report) , HBO Max, Peacock and Apple TV+ by Apple (AAPL Free Report) as well as existing services like Amazon (AMZN Free Report) prime video in the to-be-reported quarter.

The company witnessed sluggish subscriber growth in recent times, primarily due to rising competition. In first-quarter 2021, Netflix added 3.98 million paid subscribers globally compared with the addition of 15.77 million in the year-ago quarter. The company also missed its guidance of 6 million paid-subscriber addition.

Notably, Netflix’s shares have returned 0.4% year to date compared with the Zacks Broadcast Radio and Television industry’s rally of 10.6%.

Year-to-date Performance

Zacks Investment Research
Image Source: Zacks Investment Research

However, Netflix has been dominating the streaming market driven by its diversified content offering, which is attributable to Netflix’s heavy investments in production and distribution of localized, foreign-language content and an expanding international footprint.

Netflix’s content strength is evident from the fact that it recently received the highest number of Emmy nominations for the second year in a row.

Moreover, Netflix is expected to have benefited from increased consumption of media content especially originals — both movies and TV shows despite partial easing in coronavirus-induced social distancing norms and nationwide.

This Zacks Rank #3 (Hold) company expects to end the second quarter of 2021 with 208.64 million paid subscribers globally, indicating growth of 8.1% from the year-ago quarter’s levels. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The Zacks Consensus Estimate for paid memberships at the end of the period is pegged at 208.68 million, slightly better than management’s expectation.

Netflix’s second-quarter 2021 subscriber growth is expected to have been driven by a strong slate of releases that included Oxygen, Skater Girl, Awake, Army of the Dead, Shadow and Bone and The Upshaws.

The Zacks Consensus Estimate for paid total streaming net membership addition is pegged at 1.04 million, slightly better than Netflix’s expectation of 1 million but lower than the year-ago quarter’s reported figure of 10.09 million.

Netflix’s growing popularity in Asia Pacific (APAC) and Latin America (LATAM), thanks to its diversified content offerings in regional languages, is expected to have driven top-line growth.

The consensus mark for second-quarter 2021 APAC revenues is pegged at $786 million, indicating 38.1% growth from the figure reported in the year-ago quarter. Further, the Zacks Consensus Estimate for LATAM revenues is pegged at $865 million, suggesting almost 10.2% growth from the figure reported in the previous quarter.

The consensus estimate for the Europe, Middle East & Africa (EMEA) revenues is pegged at $2.40 billion, suggesting 26.9% growth from the figure reported in the year-ago quarter.

The consensus mark for United States and Canada (UCAN) revenues is at $3.21 billion, indicating 13.2% growth from the figure reported in the previous quarter.